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Introduction: Positron emission tomography-computed tomography (PET/CT) is a well established method for the staging of malignant 
lymphoma, and 18F-fluorodeoxyglucose (18F-FDG) uptake, quantified by standardized uptake value (SUV), is a marker for the level of tumor 
metabolic activity.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS) is an emerging MR technique 
showing promises in tumor assessment.  As cellular density is higher in tumor tissue compared to normal tissue, extracellular space, and thus, 
free diffusion of water is reduced. Therefore, apparent diffusion coefficient (ADC), a quantitative parameter measured on DWI, maybe regarded 
as a biomarker for evaluating the cellularity of solid tumors.  The aim of this study was to evaluate the diagnostic performance of DWIBS in 
detection of lymphoma compared with PET/CT, and to assess the correlation between ADC and SUV in lymphoma lesions.   
Materials and Methods: 24 consecutive patients with pathologically confirmed newly-diagnosed lymphoma (6 aggressive B cell, 9 indolent B 
cell, 6 NK/T cell, 3 Hodgkin’s lymphoma) who were untreated and having undergone both MRI and PET/CT within a 1 week time frame were 
included in this study.  MR examinations were performed on a 3T scanner (Achieva; Philips Healthcare). Flex-L and Flex-M coils were placed 
over abdomen and pelvis. Q-body coil was used to cover head and chest. DWIBS was performed in the transversal orientation using the 
following parameters: TR/TE/TI=7779/48/260 ms; FOV=40×33 cm; matrix=188×159; slice thickness=5 mm; gap=0; b value=0 and 1000 s/mm2; 
number of acquisitions=4; EPI factor=83; SENSE factor=2.  5 stacks were performed to include coverage from head to the distal thighs. All 
PET/CT examinations were performed on the same scanner (Discovery VCT, GE Healthcare Bio-Sciences Corp.).  A whole body PET scan 
with a 70-cm axial FOV,  218×218 matrix,3.27 mm thickness was obtained with five bed positions within 20 minutes. CT images were 
performed using the following scan parameters: FOV=50cm, matrix=512×512, collimation=0.625 mm×64, pitch=0.984, gantry rotation 
speed=0.5 second, tube voltage=120 kVp, and tube current=200-400 mA. The CT images were then reconstructed at 2.5mm intervals to fuse 
with the PET images (Advantage Workstation 4.3; GE Healthcare).  The PET/CT and DWIBS images were reviewed by experienced 
radiologists blinded to the findings of the other imaging modality, and all lesions detected were recorded.  ADC map was reconstructed using 
the standard software on the imaging console (Achieva; Philips Healthcare). ROIs were manually drawn along contours of each lesion on ADC 
maps on every slice covering the entire lesion. ADCmin is defined as the lowest ADC value among all voxels in each lesion.  SUVmax 
(maximum standardized uptake value) was automatically measured from a 3D ROI which was placed over the entire lesion. ADCmin and 
SUVmax for the most hypermetabolic lesion per patient were recorded for analysis.  Pearsons correlation test was used to detect the relationship 
between ADCmin and SUVmax. One way ANOVA post hoc test was used to compare the differences of ADCmin and SUVmax between four 
types of lymphoma (aggressive B-cell, indolent B-cell, NK/T cell and Hodgkin’s lymphoma). The findings detected on DWIBS and PET/CT 
images were compared on a per-lesion basis to determine true-positive (TP), false-negative (FN), and false-positive (FP) rates using PET/CT as 
the gold-standard.  
Results: 115 and 104 lesions were detected on PET/CT and DWIBS respectively. 100 lesions (87.0%) were concordant on PET/CT and DWIBS.  
19 lesions were discordant. Of the discordant lesions, 15 lesions were detected on PET/CT but not DWIBS whilst 4 lesions were detected on 
DWIBS but not PET/CT (Table 1). TP, FN and FP of DWIBS in lymphoma lesion detection were 90.4%, 9.6% and 3.5% (Table 2). ADCmin 
(mean±S.D.) was 0.39±0.13 x 10-3 mm2/s in indolent B-cell lymphomas, 0.21±0.10 x 10-3 mm2/s in aggressive B-cell lymphomas, 0.26±0.07 
x 10-3 mm2/s in NK/T cell lymphomas, and 0.34±0.15 x 10-3 mm2/s in Hodgkin’s lymphoma.  SUVmax (mean±S.D.) was 5.4±3.6 in indolent 
B-cell lymphomas, 12.7±4.8 in aggressive B-cell lymphomas, 8.8 ±6.6 in NK/T cell lymphomas, and 8.3 ±4.9 in Hodgkin’s lymphoma. 
There were no overall significant differences of SUVmax and ADCmin between four groups of lymphoma (p=0.071), although SUVmax was 
significantly lower in indolent than in aggressive B-cell lymphoma (p=0.012) and ADCmin was significantly higher in indolent than in 
aggressive B-cell lymphoma (p=0.024) (Figure 1). Significant negative correlation was found between SUVmax and ADCmin (r=-0.575, p< 0.01) 
of indolent B-cell and aggressive B-cell lymphoma (Figure 2).  
Conclusion: (1) DWIBS provides satisfactory diagnostic accuracy in lymphoma compared with PET/CT, and with the advantage of no ionizing 
radiation. Evaluation of T1-weighted and T2-weighted MRI together with DWIBS should improve accuracy. (2) There were significant 
differences in both ADCmin and SUVmax between aggressive and indolent B-cell lymphoma. ADCmin may therefore be another useful 
quantitative marker for tumor characterization and classification. (3) Negative correlation was found between ADCmin and SUVmax suggesting 
an association between tumor cellularity and metabolic activity.   Reference: (1). Schoder H, et al. J Clin Oncol 2005; 23:4643-4651. (2). 
Juweid ME, et al. J Clin Oncol 2005; 23:4577-4580. (3). Bohlscheid A, et al. Rofo 2008; 180:302-309.        
 
 
 
 
 
                                  
 
 
 
 
 
Table 2 Qualitative analysis of DWIBS tested against PET/CT 
 TP FN FP 
DWIBS 90.4% 9.4% 3.5% 
 
Table 1 Summary of discordant lesions on PET/CT and DWIBS  
Discordant Lesion  n = 19 DWIBS (D) / PET(P) (－) Size (mm) 
Lymph node, cervical  2 D 11.1, 28.9 
Lymph node, mediastinal  3 D 10.1, 14.4, 14.7 
Brain 1 D 11.6 
Nasopharynx 2 D 15.5, 15.8 
Lung  1 D 24.9 
Kidney  2 D 26.8, 30.9 
Bone, T1, T7, L3, rib  4 D 13.0, 18.7, 13.4, 16.8 
Lymph node, abdomen and pelvis 3 P 16.5, 18.5, 21.2 
Liver 1 P 30.5 
 
Figure 1: Box plot showing distribution of SUVmax (A) and 
ADCmin (B) among indolent B-cell, aggressive B-cell, NK/T 
B-cell, and Hodgkin’s lymphoma. The box represents the lower and 
upper quartiles and the median is marked with a horizontal line 
inside the box. Outlying observations in (A) and (B) were matched 
for each other in NK/T cell lymphoma.  
Figure 2: Scatter plot showing 
the significant negative 
correlation between ADCmin 
and SUVmax. ∆=aggressive 
B-cell lymphomas, 〇=indolent 
B-cell lymphoma. 
 
